Slc6a1 Connect
We are a research-focused patient advocacy group dedicated to accelerating the development of novel therapeutic approaches for all with SLC6A1-Related Disorders, a newly identified neuro-developmental disorder, by improving the lives of those affected.
06/23/2026
What do you do when one of the strongest voices in rare disease advocacy moves to your hometown? ðŸ¤
You celebrate him like crazy.
Welcome to DFW, Dennis Lal! Yee haw! We are beyond excited to have you here and incredibly grateful for your partnership, leadership, and commitment to the rare disease community.
Texas rare disease momentum is building. 🚀
This Father’s Day, we celebrate the dads who show up every single day for children with rare diseases.
The dads who become nurses, therapists, advocates, researchers, and fierce protectors. The dads who stay up through sleepless nights, learn complex medical terminology, fight insurance denials, travel across the country for appointments, and never stop believing that a better future is possible.
At SLC6A1 Connect, we have the privilege of knowing so many extraordinary fathers. They do this work not for recognition, but because they love their children beyond measure.
Every day, we witness incredible courage and resilience—not only from our children but from the fathers who stand beside them.
This Father’s Day, we ask you to honor these dads by giving them something priceless: hope.
Your donation helps fund research, accelerate treatments, support families, and bring us closer to a day when every child with SLC6A1 has effective therapies and every parent can dream bigger for their child’s future.
Because every dad deserves the chance to see their child thrive.
Please consider making a gift today in honor of the rare disease dads who never give up. 💙
06/19/2026
is looking forward to attending the Biotechnology Innovation Organization (BIO) conference and participating in a storytelling session on Tuesday.
Why is BIO important? The Biotechnology Innovation Organization is the world’s largest trade association representing the biotechnology industry. It brings together scientists, companies, advocates, investors, and policymakers working to transform medicine and accelerate innovation.
Why does this matter? Because for rare disease families, this is not theoretical. We are in a fight for our lives.
https://download-video-ak.vimeocdn.com/v3-1/playback/52378862-61d4-4b88-8783-bb7976cf10e0/3e6cb063-c6dc291b?__token__=st=1779742257~exp=1779745857~acl=%2Fv3-1%2Fplayback%2F52378862-61d4-4b88-8783-bb7976cf10e0%2F3e6cb063-c6dc291b%2A~hmac=a107bea09e7f612d150119131b21a028a9861820acd3313f7085c96c51cfab7f&r=dXMtZWFzdDE%3D
SLC6A1 Connect
06/18/2026
💙🌎👟 The world is walking for Will.
On June 24, employees will support their colleague -Stuart Place- across the globe at Orbis Investments will take part in the Walk for Will: 24 Hour Challenge, walking as many kilometers as possible in 24 hours to raise awareness and funding for SLC6A1, a rare and devastating neurodevelopmental disorder.
Every day, Will faces challenges that most people never see—epilepsy, developmental delays, autism, movement difficulties, and behaviors that impact every aspect of daily life. Families like ours fight battles that are exhausting, heartbreaking, and often invisible.
That is why this means so much.
A company halfway around the world decided that our children are worth walking for. Hundreds of people will lace up their shoes, track their miles, and help move research forward. Every step is a reminder that our families are not alone.
To everyone at Orbis: thank you for choosing to walk for Will, and for every child and family living with SLC6A1. You are helping turn hope into action.
💙 Every step drives awareness.
💙 Every kilometer funds progress.
💙 Every participant makes a difference.
06/12/2026
Big news for the community! 🎉
We are incredibly proud to share that SLC6A1 has been selected to participate in the Aligning Research to Impact Autism | ARIA, an international effort designed to accelerate clinical trial readiness and therapeutic development for severe autisms! The ARIA Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network is creating a coordinated global infrastructure that works together to accelerate clinical trial readiness and therapeutic development for autism and related neurodevelopmental conditions.
For our families, this is profound. It means SLC6A1 is no longer waiting on the sidelines. It is part of a national mission with the resources and urgency to match our own.
This is what years of relentless advocacy looks like. Thank you to every family who shared your story and refused to let SLC6A1 be ignored.
Advancing Research. Supporting Families. Driving Hope.
Too Rare to Ignore. Too Important to Abandon.
Learn more at www.slc6a1connect.org
06/10/2026
This will be someday. So proud of Mahzi Therapeutics for advancing this technology.
The infant was one of the first in the world to be treated.
06/09/2026
🧬 New SLC6A1 Research Published!
A new publication highlights the broad clinical spectrum of SLC6A1-related neurodevelopmental disorder and reinforces what families have known for years: SLC6A1 affects far more than seizures. The disorder impacts development, communication, behavior, movement, sleep, and quality of life for both patients and caregivers.
Studies like this are important because they help researchers, clinicians, regulators, and industry better understand the full burden of disease and the outcomes that matter most to families. As therapies advance into clinical development, having a comprehensive understanding of the patient experience becomes increasingly critical.
Every publication adds another piece to the puzzle and brings us one step closer to better treatments for individuals living with SLC6A1.
Thank you to the researchers, clinicians, patients, and families whose participation makes this work possible.
📖 Read the publication here:
https://pubmed.ncbi.nlm.nih.gov/42173049/
Click here to claim your Sponsored Listing.
Category
Website
Address
1939 Temperence Hill Drive
Frisco, TX
75034
